Alterome Therapeutics
Alteration-specific small molecule therapeutics targeting AKT E17K and KRAS mutations in cancer
- Sector
- Biotech
- Headquarters
- SAN MARCOS, CA
- Founded
- 2021
- Latest Form D
- $63.8M, Jan 2022
- Total capital
- $63.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $63.8M
- 1 Form D · last Jan 2022
- 57 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2024
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$63.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arjun B. GoyalDirectorNamed in SEC Form D filings
- Carl B. GordonDirectorNamed in SEC Form D filings
- Eric A. MurphyExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Ryan B. CorcoranDirector, PromoterNamed in SEC Form D filings
- Thilo B. SchroederDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingAKT1 ModulatorsUSPTOApplication 19128308
- GrantedSUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSUSPTOUS 12,528,828
- PendingSUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSUSPTOApplication 19271639
Show all 40 patent records
- AKT1 ModulatorsJul 9, 2026 · Application 19128308Pending
- SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSJan 20, 2026 · US 12,528,828Granted
- SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSNov 13, 2025 · Application 19271639Pending
- SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSNov 11, 2025 · US 12,466,842Granted
- AKT1 ModulatorsMar 20, 2025 · Application 18955505Pending
- AKT1 ModulatorsJan 28, 2025 · US 12,209,087Granted
- AKT1 ModulatorsJun 4, 2024 · US 11,999,730Granted
- Pharmaceutical Formulations Comprising An AKT1 InhibitorApplication 63870432Pending
- Kras ModulatorsApplication 63887275Pending
- Kras ModulatorsApplication PCTUS2025054025Pending
- Kras ModulatorsApplication 63825319Pending
- AKT1 ModulatorsApplication PCTUS2025031050Pending
- Kras ModulatorsApplication 19158394Pending
- AKT1 ModulatorsApplication 19128304Pending
- Kras ModulatorsApplication 63825192Pending
- Substituted PYRIDO[4,3-D]PYRIMIDINES As Kras ModulatorsApplication PCTUS2025036438Pending
- Pharmaceutical Formulations Comprising An AKT1 InhibitorApplication PCTUS2025050356Pending
- AKT1 ModulatorsApplication PCTUS2025021322Pending
- Kras ModulatorsApplication 63774493Pending
- Kras ModulatorsApplication 63774503Pending
- Kras ModulatorsApplication 63774510Pending
- Kras ModulatorsApplication 63774512Pending
- Treatment Of Cancer With A Kras InhibitorApplication 63774023Pending
- AKT1 ModulatorsApplication 63767446Pending
- Salts Of An Kras Inhibitor And Crystalline Solid Forms ThereofApplication PCTUS2026017330Pending
- Pharmaceutical Formulations Comprising A Kras InhibitorApplication PCTUS2026017321Pending
- Kras ModulatorsApplication 63737425Pending
- Kras ModulatorsApplication 19158387Pending
- Treatment Of Cancer With An AKT1 InhibitorApplication PCTUS2025021356Pending
- Pharmaceutical Formulations Comprising A Kras InhibitorApplication 63766867Pending
- AKT1 ModulatorsApplication 19106008Pending
- AKT1 ModulatorsApplication 19106010Pending
- Solid State Forms Of An AKT1 Inhibitor And Salts ThereofApplication PCTUS2025021362Pending
- AKT1 ModulatorsApplication PCTUS2025018196Pending
- AKT1 ModulatorsApplication PCTUS2025018205Pending
- Kras ModulatorsApplication 63778291Pending
- Kras ModulatorsApplication 63737481Pending
- AKT1 ModulatorsApplication PCTUS2024059786Pending
- Preparation Of IMIDAZO[4,5-B]PYRIDINE AKT1 InhibitorsApplication PCTUS2025043576Pending
- Treatment Of Cancer With A Kras InhibitorApplication PCTUS2025052115Pending
Related companies, and why
- CHINA PHARMA HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
- iToleranceSimilar federal contract value in Biotech · null in contracts
- IZUN PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
- Outpace BioSimilar federal contract value in Biotech · null in contracts
- Chemomab Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Lumena Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .